newsfilter
← Latest News
ClinicalTrials.gov·

A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - NCT05421663

Incidence of Adverse Events [Safety and Tolerability], The recommended Phase 2 dose (RP2D) of C-CAR039 in patients with r/r B-NHL, Overall response rate (ORR), (and 7 more...)